Ketan K Badani, MD Email Ketan Badani
- PROFESSOR | Urology
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
- Mount Sinai Queens
Book an Appointment - Ketan K Badani, MD
Dr. Ketan K. Badani is Professor of Urology, Icahn School of Medicine at Mount Sinai, Vice Chairman of Urology and Robotic Operations at Mount Sinai Health System, Director of Robotic Surgery at Mount Sinai West, and the Director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System.
Dr. Badani is recognized as a world leader in the research and treatment of urologic oncology. Specifically, he has focused his work on prostate and kidney cancer. Dr. Badani has led teams that first developed and published techniques for minimally invasive robotic kidney cancer surgery. His technique of robotic partial nephrectomy, The “F.A.S.T.” procedure has been published and taught around the world to treat patients with renal tumors. Dr. Badani leads a team seeking to improve treatment of these cancers by finding less invasive and effective therapy, while maintaining quality of life factors after surgery.
Dr. Badani has performed nearly 4,000 robotic procedures in his career, placing him in the top 1% of urologists worldwide. He is one the preeminent practitioners in the world for robotic partial nephrectomy for complex kidney tumors, and robotic prostatectomy for localized prostate cancer; he has the largest combined experience in robotic kidney and prostate cancer in the New York area. Dr. Badani’s clinical expertise spans both surgical and non-surgical approaches to treatment of urologic cancers. He has just completed one of the largest decision impact studies evaluating genomic biomarkers for active surveillance in men with low risk prostate cancer.
As Visiting Professor, Dr. Badani has given lectures and demonstrated surgery in over 20 countries. Most recently he visited prominent institutions in the United States, Canada, Brazil, Japan, India, Malaysia, Venezuela, China, Spain, and Turkey to teach his technique. He is the author of over 150 peer-reviewed publications and has presented over 200 abstracts at national and international meetings. He has led the prostate and kidney cancer research program at Columbia University Medical Center for the past 7 years. Dr. Badani is involved in numerous clinical trials, feasibility and safety studies of new technology, and health related quality of life outcomes research. He serves as an editor and/or reviewer for numerous publications including Cancer, Journal of Urology, Urologic Oncology, Journal of Endourology, among others.
As Director of the Comprehensive Kidney Cancer Program at Mount Sinai Heath System, Dr. Badani will develop a multispecialty clinical program for kidney cancer patients that will span the treatment spectrum including surgery, nephrology, interventional radiology, and complementary medicine. Clinically, the program will allow individualized care to each patient with kidney cancer based on the tumor stage, grade, and overall health. Academically, the program will be on the cutting edge for innovative technology based research, and latest clinical trials.
Dr. Badani graduated in the top of his class from Case Western Reserve University School of Medicine in Cleveland, Ohio. He went on to complete his urology residency at the world renowned Vattikuti Urology Institute at Henry Ford Hospital in Detroit, MI (his hometown). He also completed a fellowship in minimally invasive urologic oncology at the Vattikuti Urology Institute, where robotic urologic surgery was first performed in the United States. Upon completion of his training, Dr. Badani joined the faculty at Columbia University Medical Center.
Dr. Badani will see patients at two locations: Mount Sinai Hospital (5 East 98th Street) and Mount Sinai West (425 West 59th Street). His office can be contacted by calling (212)241-3919. He can be reached via email at email@example.com.
Dr. Badani Patient Stories:
American Board of Urology
- Bladder Cancer
- Congenital Kidney Disease
- Elevated PSA
- Frequent Urination
- Kidney Cancer
- Kidney Stones
- Low Libido
- Low Testosterone
- Neurogenic Bladder
- Penile Cancer
- Premature Ejaculation
- Prostate Biopsy
- Prostate Cancer
- Prostate Cancer Screening
- Prostate-Specific Antigen (PSA) Test
- Radical Cystectomy
- Robotic Kidney Surgery
- Robotic Prostate Surgery
- Testicular Cancer
- Urology Second Opinion
MD, Case Western Reserve University
Henry Ford Health Systems
Fellowship, Robotic Urology
Henry Ford Health Systems
Best research poster Robotic Surgery
World Congress of Endourology
Best research poster Kidney Cancer
American Urological Association Annual Meeting
Cullman Family Award for Excellence in Physician Communication
Mount Sinai Health System
Rising Star Award
Honorary Editorial Board Member
Robotic Surgery Research and Reviews
Best research poster
AUA Annual Meeting
Best of ther Best - Video - honorable Mention
AUA Annual Meeting
Outstanding Contribution Award
International Prostate Cancer Symposium
Nominee Surgeon of the Year
New York Presbyterian Hospital
America's top Surgeons
Consumers Research Council of America
America;s Top Urologists
Consumers Research Council of America
Castle Connelly Top Docs 2013-2017
America's Top Surgeons 2011-2017
Korets R, Weinberg AC, Alberts BD, Woldu SL, Mann MJ, Badani KK. Utilization and Timing of Blood Transfusions Following Open and Robot Assisted Radical Prostatectomy. Journal of endourology / Endourological Society 2014 Aug;.
Weinberg AC, Woldu SL, Bergman A, Roychoudhury A, Patel T, Berg W, Wambi C, Badani KK. Dorsal penile nerve block for robot-assisted radical prostatectomy catheter related pain: a randomized, double-blind, placebo-controlled trial. SpringerPlus 2014; 3.
Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU international 2014 Apr;.
Berg WT, Shapiro EY, Rothberg MB, Bergman A, Scarberry K, Wambi C, Patel T, Badani KK. Baseline Serum 25-Hydroxyvitamin D Levels in Men Undergoing Radical Prostatectomy: Is There An Association With Adverse Pathologic Features?. Clinical genitourinary cancer 2014 Feb;.
Woldu SL, Weinberg AC, Bergman A, Shapiro EY, Korets R, Motamedinia P, Badani KK. Pain and analgesic use after robot-assisted radical prostatectomy. Journal of endourology / Endourological Society 2014 May; 28(5).
Woldu SL, Patel T, Shapiro EY, Bergman AM, Badani KK. Outcomes with delayed dorsal vein complex ligation during robotic assisted laparoscopic prostatectomy. The Canadian journal of urology 2013 Dec; 20(6).
Al-Daghmin A, Kauffman EC, Shi Y, Badani K, Balbay MD, Canda E, Dasgupta P, Ghavamian R, Grubb R, Hemal A, Kaouk J, Kibel AS, Maatman T, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi R, Palou Redorta J, Rha KH, Richstone L, Schanne F, Scherr DS, Siemer S, Stöckle M, Wallen EM, Weizer A, Wiklund P, Wilson T, Wilding G, Woods M, Guru KA. Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC). BJU international 2014 Jul; 114(1).
Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, Scherr DS, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. European urology 2014 Feb; 65(2).
Pollard ME, Levinson AW, Shapiro EY, Cha DY, Small AC, Mohamed NE, Badani KK, Gupta M. Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model. Urology 2013 Dec; 82(6).
Patel T, Wambi C, Berg WT, Bergman A, Shapiro EY, Badani KK. Characterization of perioperative leukocytosis in patients undergoing robot-assisted radical prostatectomy: effects of Gleason score and race. Journal of endourology / Endourological Society 2013 Dec; 27(12).
Patel T, Wambi CC, Berg W, Inusa MD, Menon M, Badani K. Prostate cancer disease characteristics for foreign-born South Asian men living in the United States. Indian journal of cancer; 50(3).
Shapiro EY, Scarberry K, Patel T, Bergman A, Ahn JJ, Sahi N, RoyChoudhury A, Deutch I, McKiernan JM, Benson MC, Badani KK. Comparison of robot-assisted and open retropubic radical prostatectomy for risk of biochemical progression in men with positive surgical margins. Journal of endourology / Endourological Society 2014 Feb; 28(2).
Patel T, Wambi C, Berg WT, Bergman A, Shapiro EY, Badani KK. Characterization of Perioperative Leukocytosis in Patients undergoing Robotic assisted Retropubic Prostatectomy: Effects of Gleason score and Race. Journal of endourology / Endourological Society 2013 Sep;.
Badani KK, Shapiro EY, Berg WT, Kaufman S, Bergman A, Wambi C, Roychoudhury A, Patel T. A Pilot Study of Laparoscopic Doppler Ultrasound Probe to Map Arterial Vascular Flow within the Neurovascular Bundle during Robot-Assisted Radical Prostatectomy. Prostate cancer 2013; 2013.
Borregales LD, Berg WT, Tal O, Wambi C, Kaufman S, Gaya JM, Urzúa C, Badani KK. 'Trifecta' after radical prostatectomy: is there a standard definition?. BJU international 2013 Jul; 112(1).
Rosen DC, Paulucci DJ, Abaza R, Eun D, Bhandari A, Hemal A, Badani KK. Is Off Clamp Always Beneficial During Robotic Partial Nephrectomy? A Propensity Score Matched Comparison of Clamp Technique in Patients with Two Kidneys. Journal of endourology 2017 Sep;.
Khan I, Beksac AT, Paulucci DJ, Abaza R, Eun DD, Bhandari A, Badani KK. Differences in Renal Tumor Size Measurements for Computed Tomography Versus Magnetic Resonance Imaging: Implications for Patients on Active Surveillance. Journal of laparoendoscopic & advanced surgical techniques. Part A 2017 Aug;.
Reynolds CR, Delto JC, Paulucci DJ, Weinstein C, Badani K, Eun D, Abaza R, Porter J, Bhandari A, Hemal AK. Comparison of perioperative and functional outcomes of robotic partial nephrectomy for cT1a vs cT1b renal masses. BJU international 2017 Jul;.
Beksac AT, Paulucci DJ, Blum KA, Yadav SS, Sfakianos JP, Badani KK. Heterogeneity in renal cell carcinoma. Urologic oncology 2017 Aug; 35(8).
Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD, Bhandari A, Hemal AK, Sfakianos JP, Badani KK. Predicting Complications Following Robot-Assisted Partial Nephrectomy with the ACS NSQIP(®) Universal Surgical Risk Calculator. The Journal of urology 2017 Oct; 198(4).
Beksac AT, Paulucci DJ, Sfakianos JP, Reddy BN, Gin GE, Lerner SM, Badani KK. Trends in management of the small renal mass in renal transplant recipient candidates: A multi-institutional survey analysis. Urologic oncology 2017 Aug; 35(8).
Paulucci DJ, Sfakianos JP, Skanderup AJ, Kan K, Tsao CK, Galsky MD, Hakimi AA, Badani KK. Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma. Oncotarget 2017 Jan; 8(3).
Hussein AA, Saar M, May PR, Wijburg CJ, Richstone L, Wagner A, Wilson T, Yuh B, Redorta JP, Dasgupta P, Khan MS, Menon M, Peabody JO, Hosseini A, Gaboardi F, Mottrie A, Rha KH, Hemal A, Stockle M, Kelly J, Maatman TJ, Canda AE, Wiklund P, Guru KA. Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. The Journal of urology 2017 Jun; 197(6).
Paulucci DJ, Abaza R, Eun DD, Hemal AK, Badani KK. Robot-assisted partial nephrectomy: continued refinement of outcomes beyond the initial learning curve. BJU international 2017 May; 119(5).
Moskowitz EJ, Paulucci DJ, Reddy BN, Blum KA, Rosen DC, Abaza R, Eun DD, Hemal AK, Krane LS, Badani KK. Predictors of Medical and Surgical Complications After Robot-Assisted Partial Nephrectomy: An Analysis of 1139 Patients in a Multi-Institutional Kidney Cancer Database. Journal of endourology 2017 Mar; 31(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Badani did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.